Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/41161
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSanchez-Niño, Maria Dolores
dc.contributor.authorSanz, Ana B
dc.contributor.authorRamos, Adrian M
dc.contributor.authorFernandez-Fernandez, Beatriz
dc.contributor.authorOrtiz, Alberto
dc.date.accessioned2019-07-31T11:47:23Z-
dc.date.available2019-07-31T11:47:23Z-
dc.date.issued2017-04
dc.identifier.citationClin Kidney J.2017 Apr;(10)2:188-191
dc.identifier.issn2048-8505
dc.identifier.urihttps://hdl.handle.net/20.500.12530/41161-
dc.description.abstractExponential technologies double in power or processing speed every year, whereas their cost halves. Deception and disruption are two key stages in the development of exponential technologies. Deception occurs when, after initial introduction, technologies are dismissed as irrelevant, while they continue to progress, perhaps not as fast or with so many immediate practical applications as initially thought. Twenty years after the first publications, clinical proteomics is still not available in most hospitals and some clinicians have felt deception at unfulfilled promises. However, there are indications that clinical proteomics may be entering the disruptive phase, where, once refined, technologies disrupt established industries or procedures. In this regard, recent manuscripts in CKJ illustrate how proteomics is entering the clinical realm, with applications ranging from the identification of amyloid proteins in the pathology lab, to a new generation of urinary biomarkers for chronic kidney disease (CKD) assessment and outcome prediction. Indeed, one such panel of urinary peptidomics biomarkers, CKD273, recently received a Food and Drug Administration letter of support, the first ever in the CKD field. In addition, a must-read resource providing information on kidney disease-related proteomics and systems biology databases and how to access and use them in clinical decision-making was also recently published in CKJ.
dc.language.isoeng
dc.rightsopenAccess-
dc.titleClinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase.
dc.typeArtículo
dc.identifier.pubmedID28396735
dc.format.volume10
dc.format.page188-191
dc.identifier.journalClinical kidney journal
dc.identifier.doi10.1093/ckj/sfx023
dc.format.number2
dc.identifier.pmcPMC5381206
dc.pubmedtypeJournal Article
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
PMC5381206.pdf447.4 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.